Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance.
- befree-2016 importedOn "2016-02-19" NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance.
- NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_assertion wasGeneratedBy ECO_0000203 NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance.
- NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_assertion wasDerivedFrom befree-2016 NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance.
- NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_assertion SIO_000772 24685829 NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance.
- NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_assertion evidence source_evidence_literature NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance.
- NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_assertion description "[Results from the phase III trial CLEOPATRA in human epidermal growth factor receptor 2-positive first-line metastatic breast cancer demonstrated significant improvements in progression-free and overall survival with pertuzumab, trastuzumab, and docetaxel over placebo, trastuzumab, and docetaxel.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1168972.RAHds6Or7kjPnVn36_6RQjS8-BC_TJn9SlR9qbShdIEtI130_provenance.